AstraZeneca Profit, Revenue Lifted by Cancer Drugs

AstraZeneca Plc reported better-than-expected sales and rising profit for the second quarter, spurred by its stable of cancer medicines and growth in the US.

Revenue climbed 12% to $14.5 billion, the UK drugmaker said Tuesday, beating estimates. Earnings per share excluding some items rose 10% to $2.17, as expected. The shares climbed 1.4% in London trading, pushing their gain for the year beyond 4%.